Sign in

The Lancet Infectious Diseases

@thelancetinfdis.bsky.social
2.8K followers 52 following 422 posts

The Lancet Infectious Diseases is the leading clinical infectious diseases journal for peer-reviewed research and review, comment, and news. 🌐 www.thelancet.com/journals/laninf/h…

PostsRepliesMedia
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 16h
New Research Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study www.thelancet.com/journals/lan...
thelancet.com
Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study
A novel Pfkelch13 mutation clinically associated with partial resistance to artemisinin is spreading in Zambia. Additional clinical evaluations are urgently needed in the region.
023
Reposted by The Lancet Infectious Diseases
The Lancet Reg Health-Europe @lancetrh-europe.bsky.social · 01/10/2026
What is the real-world impact of HPV vaccination in Germany? Using Bavarian health claims and prescription data from 669,053 women, this study found full vaccination was associated with a 65% lower adjusted risk of invasive cervical cancer. Read more 👇 shorturl.at/Cjxcy
shorturl.at
The effect of HPV vaccination on precancerous lesions and invasive cervical cancer in a low-vaccination-coverage setting in Germany: a retrospective cohort analysis
HPV vaccination is associated with a lower incidence of precancerous lesions and invasive cervical cancer. This is the first direct evidence of the effectiveness of the HPV vaccine in Germany.
122
Reposted by The Lancet Infectious Diseases
The Lancet Microbe @lancetmicrobe.bsky.social · 03/10/2026
Our October issue is now online: www.thelancet.com/journals/lan... Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #AMR #influenza #Streptococcus #Shigella #melioidosis #tuberculosis #IDSky #ClinMicro #MicroSky #ViroSky #MycoSky #OA
October issue cover
044
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 02/10/2026
New Research Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children: a randomised, active-controlled and placebo-controlled, phase 2b trial bit.ly/4y2rqbJ
thelancet.com
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children aged 6–17 yea...
BPZE1 was well tolerated in children aged 6–17 years, and induced robust nasal S-IgA responses to B pertussis WCE without interference from simultaneously administered Tdap. BPZE1 vaccination did not ...
101
Reposted by The Lancet Infectious Diseases
The Lancet Microbe @lancetmicrobe.bsky.social · 30/09/2026
New research article Epidemiology and phylogenomic characterisation of the 2025 #Ebola virus disease outbreak in Bulape, Kasaï province, Democratic Republic of the Congo: a retrospective observational study www.thelancet.com/journals/lan... #IDSky #ClinMicro #MicroSky #ViroSky #OpenAccess #OA
036
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 29/09/2026
New Review Methodological quality and risk of bias in non-randomised comparative effectiveness studies of invasive mould infections: a systematic review www.thelancet.com/journals/lan...
thelancet.com
Methodological quality and risk of bias in non-randomised comparative effectiveness studies of invasive mould infections: a systematic review
Many treatment recommendations for invasive mould infections, particularly those caused by rare moulds, rely on non-randomised comparative effectiveness research (CER), which is vulnerable to design a...
033
Reposted by The Lancet Infectious Diseases
eClinicalMedicine – The Lancet Discovery Science @eclinicalmed.bsky.social · 28/09/2026
Global, regional, and national burden of #tetanus in 204 countries and territories, 1990–2023: analysis for the GBD Study 2023 Over the past 3 decades, global initiatives such as EPI and MNTE have led to a substantial reduction in the burden of tetanus www.thelancet.com/journals/ecl... #MedSky
012
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 24/09/2026
Read our October issue, live now! Featuring a new regimen with quabodepistat for tuberculosis, oral care for preventing hospital-acquired pneumonia, and tocilizumab for severe hantavirus pulmonary syndrome. bit.ly/4xDKa0Z
002
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 23/09/2026
New Research Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial www.thelancet.com/journals/lan...
thelancet.com
Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial
Benznidazole 150 mg once daily for 30 days showed non-inferior efficacy and the lowest rate of drug-related adverse events among the regimens tested, supporting its adoption as the preferred benznidaz...
000
Reposted by The Lancet Infectious Diseases
The Lancet Microbe @lancetmicrobe.bsky.social · 16/09/2026
New research article Evaluation of the effect of serotype on pneumococcal conjugate #vaccine induced immunity: an exploratory analysis of the PREVENTING PNEUMO 2 trial www.thelancet.com/journals/lan... #IDSky #ClinMicro #MicroSky #Streptococcus #OpenAccess #OA
033
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 16/09/2026
New Research The risk of mpox false positive results in high transmission settings: evidence from a multi-site observational study in DR Congo www.thelancet.com/journals/lan...
thelancet.com
The risk of mpox false positive results in high transmission settings: evidence from a multi-site observational study in DR Congo
More than one in three qPCR-positive mpox diagnoses in these settings might have been driven by the environmental MPXV DNA burden, with serological data independently supporting this finding. Strength...
111
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 11/09/2026
New Research Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial www.thelancet.com/journals/lan...
thelancet.com
Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial
In adults aged 50 years or older, aQIVc was non-inferior and superior to aQIV for all four influenza strains and non-inferiority criteria for aQIVc versus QIVr were met for A/H1N1 and both B strains, ...
111
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 09/09/2026
New Personal View Is a tiered classification framework needed for sexually transmitted infections? www.thelancet.com/journals/lan...
thelancet.com
Is a tiered classification framework needed for sexually transmitted infections?
Working definitions of a sexually transmitted infection (STI) exist, but no universally agreed operational classification links those definitions to programme, funding, and surveillance decisions. The boundary of the STI category determines which infections enter surveillance, receive programme funding, and are included in testing and screening. Yet, the fields of microbiology, clinical medicine, and public health each define this boundary differently. Contested conditions, including bacterial vaginosis, vulvovaginal candidiasis, scabies, mpox, and sexually transmissible enteric pathogens, expose the inadequacy of the current binary classification.
133
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 09/09/2026
New Comment South Sudan's first 100 days of Bundibugyo Ebola readiness www.thelancet.com/journals/lan...
thelancet.com
South Sudan's first 100 days of Bundibugyo Ebola readiness
When the Democratic Republic of the Congo (DR Congo) and Uganda declared an outbreak of Ebola virus disease caused by Bundibugyo virus (BDBV) on May 15, 2026, South Sudan looked likely to be the next ...
033
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 08/09/2026
New Review Nucleic acid amplification testing and genome sequencing for WHO priority viruses in Africa: a scoping review www.thelancet.com/journals/lan...
thelancet.com
Nucleic acid amplification testing and genome sequencing for WHO priority viruses in Africa: a scoping review
Emerging viruses continue to pose serious public health threats across Africa, with recurrent outbreaks exposing gaps in diagnostics and surveillance systems. Nucleic acid amplification tests (NAATs) ...
022
Reposted by The Lancet Infectious Diseases
The Lancet Microbe @lancetmicrobe.bsky.social · 03/09/2026
WHO Target Product Profiles for Treatments for Dengue: Accelerating Clinical Development for Global Health paper 2 WHO target product profiles for #dengue therapeutics: an interdisciplinary analysis of ethical, regulatory, and implementation considerations www.thelancet.com/journals/lan...
002
Reposted by The Lancet Infectious Diseases
The Lancet Microbe @lancetmicrobe.bsky.social · 03/09/2026
New series WHO Target Product Profiles for Treatments for Dengue: Accelerating Clinical Development for Global Health paper 1 Accelerating the clinical development of treatments for #dengue: WHO dengue therapeutics landscape analysis and target product profiles www.thelancet.com/journals/lan...
102
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 03/09/2026
New Personal View Sepsis, endemic and emerging infectious diseases: converging concepts and clinical implications www.thelancet.com/journals/lan...
thelancet.com
Sepsis, endemic and emerging infectious diseases: converging concepts and clinical implications
Studies on the global burden of sepsis confirm its major mortality, morbidity, and societal impact, with 85% of cases and deaths occurring in low-income and middle-income countries. Importantly, these...
001
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 03/09/2026
New Research Accelerated qualification of diagnostic tests during an ongoing outbreak of Bundibugyo virus disease: a collaborative analytical validation study www.thelancet.com/journals/lan...
thelancet.com
Accelerated qualification of diagnostic tests during an ongoing outbreak of Bundibugyo virus disease: a collaborative analytical validation study
Decentralised evaluation of diagnostic test kits can facilitate emergency-use decisions, national authorisation, or regulatory review in ongoing outbreaks. This approach defines a course of action for...
023
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 03/09/2026
New Research Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study www.thelancet.com/journals/lan...
thelancet.com
Ring and community vaccination for Bundibugyo virus outbreak response: a stochastic network modelling study
Strengthened case finding, contact tracing, and isolation averted most deaths even without vaccination. Once these operations were strong, reactive ring vaccination added a modest further benefit, whe...
024
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 01/09/2026
New Research Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial www.thelancet.com/journals/lan...
thelancet.com
Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial
Nirmatrelvir–ritonavir for 15 days or 25 days showed no evidence of benefit in long COVID in any of the three phenotypes studied. These findings suggest additional approaches to measuring the symptom ...
071
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 01/09/2026
New Research Clinical accuracy, performance, and usability of the Dragonfly point-of-care molecular diagnostic platform for mpox: a mixed-methods field evaluation in Uganda www.thelancet.com/journals/lan...
thelancet.com
Clinical accuracy, performance, and usability of the Dragonfly point-of-care molecular diagnostic platform for mpox: a mixed-methods field evaluation in Uganda
Dragonfly showed high sensitivity and specificity for mpox detection across a broad range of viral loads in the field, supporting its potential as a point-of-care diagnostic in high-burden, resource-l...
011
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 26/08/2026
New Research Safety and immunogenicity of GBS6 in pregnant women living with and without HIV and their infants in Uganda (PREPARE WP4): a double-blind, randomised, placebo-controlled, phase 2 clinical trial www.thelancet.com/journals/lan...
thelancet.com
Safety and immunogenicity of GBS6 in pregnant women living with and without HIV and their infants in Uganda (PREPARE WP4): a double-blind, randomised, placebo-controlled, phase 2 clinical trial
GBS6 elicited anti-capsular polysaccharide conjugate antibodies against group B streptococcus in pregnant women that were transferred to their infants, with no evidence of a difference irrespective of...
122
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 26/08/2026
New Research Evaluating the impact of antiviral post-exposure prophylaxis for health-care workers during orthoebolavirus outbreaks: a modelling study www.thelancet.com/journals/lan...
thelancet.com
Evaluating the impact of antiviral post-exposure prophylaxis for health-care workers during orthoebolavirus outbreaks: a modelling study
HCW-targeted antiviral PEP could substantially reduce HCW deaths during orthoebolavirus outbreaks if efficacious antivirals can be delivered rapidly and high operational coverage is maintained. Compar...
011
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 24/08/2026
New Research Severe health-care-associated infections and antimicrobial resistance in an Asian Surveillance Network (ACORN-HAI): a multicentre, prospective cohort study www.thelancet.com/journals/lan...
thelancet.com
Severe health-care-associated infections and antimicrobial resistance in an Asian Surveillance Network (ACORN-HAI): a multicentre, prospective cohort study
AMR bacterial bloodstream infections and ventilator-associated pneumonia were common and associated with high mortality and reduced quality of life in Asia, particularly in infections due to carbapene...
102
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 21/08/2026
New Research Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial www.thelancet.com/journals/lan...
thelancet.com
Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, pl...
This study supports the WHO recommendation of oral azithromycin alone for treatment of clinically suspected or culture-confirmed uncomplicated typhoid fever,providing no evidence to support addition o...
010
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 20/08/2026
Read our September issue, live now! Featuring tuberculosis diagnostics in adults living with HIV, testing dose-sparing polio vaccination in India, and optimising vivax malaria therapy in Brazil. bit.ly/4xdIHz0
023
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 20/08/2026
New Research Safety and immunogenicity of the synthetic carbohydrate conjugate vaccine, SF2a-TT15, against Shigella flexneri 2a in infants in Kenya: a phase 2a, age-descending, dose-escalating, double-blind, randomised, placebo-controlled study www.thelancet.com/journals/lan...
thelancet.com
Safety and immunogenicity of the synthetic carbohydrate conjugate vaccine, SF2a-TT15, against Shigella flexneri 2a in infants in Kenya: a phase 2a, age-descending, dose-escalating, double-blind, rando...
SF2a-TT15 is well tolerated and strongly immunogenic in Kenyan infants, showing potential for further development. Available data support advancing a multivalent synthetic glycan-based Shigella vaccin...
000
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 20/08/2026
New Research Epidemiological impact of a dual-action insecticidal coating applied to Aedes aegypti breeding sites on dengue transmission in Colombia: a cluster-randomised trial www.thelancet.com/journals/lan...
thelancet.com
Epidemiological impact of a dual-action insecticidal coating applied to Aedes aegypti breeding sites on dengue transmission in Colombia: a cluster-randomised trial
The intervention reduced dengue incidence and Aedes aegypti infestation over 12 months. A single application of a dual-action insecticidal coating to domestic water containers represents a scalable an...
111
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 19/08/2026
New Research Comparison of VPM1002 with BCG in the prevention of tuberculosis in newborn infants: a multicentre, double-blind, randomised, phase 3, non-inferiority trial www.thelancet.com/journals/lan...
thelancet.com
Comparison of VPM1002 with BCG in the prevention of tuberculosis in newborn infants: a multicentre, double-blind, randomised, phase 3, non-inferiority trial
VPM1002 did not show non-inferiority to BCG on the primary endpoint of QFT conversion. Because fewer infections occurred than expected (334 of 632 planned events, despite extending the duration to 48 ...
102
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 19/08/2026
New Review COPD and Aspergillus—a complex interaction of global health importance www.thelancet.com/journals/lan...
thelancet.com
COPD and Aspergillus—a complex interaction of global health importance
Aspergillus spp are common airborne fungi, and the commonest fungal pathogen of human lungs. In patients with chronic obstructive pulmonary disease (COPD), the usual defences against disease are impai...
012
Reposted by The Lancet Infectious Diseases
The Lancet @thelancet.com · 17/08/2026
Islatravir–lenacapavir has potential to be the first once-weekly complete oral single-tablet regimen for HIV-1 treatment, suggests ISLEND-2 trial in The Lancet. Explore the research: spkl.io/6332073GCs
Research in context panel in a paper published in The Lancet entitled "Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial".
0124
Reposted by The Lancet Infectious Diseases
The Lancet Microbe @lancetmicrobe.bsky.social · 18/08/2026
New research article Effects of attenuated #influenza virus administration to young children on pneumococcal density and acquisition in UK families: a randomised controlled trial www.thelancet.com/journals/lan... #IDSky #ClinMicro #ViroSky #Streptococcus #OpenAccess #OA
012
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 16/08/2026
New Review Guiding principles for pragmatic randomised trials of tuberculosis treatments www.thelancet.com/journals/lan...
thelancet.com
Guiding principles for pragmatic randomised trials of tuberculosis treatments
Tuberculosis remains a major global health challenge, despite recent advances in drug and regimen development. Pragmatic randomised trials are needed to evaluate the effectiveness, safety, and tolerab...
021
Reposted by The Lancet Infectious Diseases
The Lancet @thelancet.com · 15/08/2026
WHO recommends 5 days of intravenous antibiotics for children hospitalised with severe community-acquired pneumonia (CAP). A new study investigated the safety of a step-down to different oral antibiotics and the shortest effective duration: spkl.io/633247MoCp
Figure showing antibiotic treatment over time by randomised drug and by randomised duration in the oral step-down groups only. The shaded areas represent 95% CIs. Times are measured from the initiation of intravenous treatment because treatment duration within randomised groups was based on the total duration of intravenous and oral antibiotics. Randomisation was within 24 h of initiation of intravenous antibiotics for all participants, with very similar durations across all groups. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.
1146
Reposted by The Lancet Infectious Diseases
The Lancet Microbe @lancetmicrobe.bsky.social · 11/08/2026
Our August issue is now online: www.thelancet.com/journals/lan... Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #malaria #mpox #tuberculosis #TB #RSV #AMR #CRE #Jingmenvirus #Streptococcus #Pseudomonas #IDSky #ClinMicro #ViroSky #OA
August issue cover
184
Reposted by The Lancet Infectious Diseases
Michael Marks @drmichaelmarks.bsky.social · 07/08/2026
Now out @lancetmicrobe.bsky.social led @elizagil.bsky.social Strep anginosus an increasingly important cause of pyogenic infections in adults & kids. Here we describe changing epidemiology within UK. Great collaboration @lshtm.bsky.social @ukhsa.bsky.social @ucl.ac.uk @greatormondst.bsky.social
thelancet.com
Streptococcus anginosus group as a cause of serious streptococcal infection in the UK: a retrospective population-based surveillance study
SAG infections, predominantly deep pyogenic collections in SBSs, are increasing in both children and adults in the UK and represent a major cause of streptococcal SBS infections. This increase is unli...
11610
Reposted by The Lancet Infectious Diseases
The Lancet Microbe @lancetmicrobe.bsky.social · 06/08/2026
New research article #Streptococcus anginosus group as a cause of serious streptococcal infection in the UK: a retrospective population-based surveillance study www.thelancet.com/journals/lan... #IDSky #ClinMicro #OpenAccess #OA
155
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 05/08/2026
New Correspondence Congolese hospital staff cohort admitted with infectious symptoms in the setting of the Bundibugyo virus outbreak, April and May 2026, Bunia, DR Congo www.thelancet.com/journals/lan...
thelancet.com
Congolese hospital staff cohort admitted with infectious symptoms in the setting of the Bundibugyo virus outbreak, April and May 2026, Bunia, DR Congo
On May 15, 2026, DR Congo announced an outbreak of Ebola disease caused by a new variant of Bundibugyo virus in Ituri Province.1 The outbreak's epicentre was Mongbwalu, a gold mining town located 80 k...
023
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 05/08/2026
New Research Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study www.thelancet.com/journals/lan...
thelancet.com
Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study
Ethiopia is the fifth sub-Saharan African country now meeting WHO confirmation criteria for ART-R. High R622I prevalence and double deletion rates, consistent with distinct selective pressures, repres...
021
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 04/08/2026
New Research Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16–26 years in Japan: a randomised, double-blind, placebo-controlled trial www.thelancet.com/journals/lan...
thelancet.com
Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16–26 years in Japan: a randomised, double-blind, placebo-controlled trial
The 9vHPV vaccine prevents anogenital persistent infection related to vaccine-targeted HPV types in males and has an acceptable safety profile. These findings support the use of the 9vHPV vaccine in m...
022
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 03/08/2026
New Review A review of Bundibugyo virus and the 2026 outbreak: lessons for epidemic preparedness www.thelancet.com/journals/lan...
thelancet.com
A review of Bundibugyo virus and the 2026 outbreak: lessons for epidemic preparedness
The ongoing 2026 outbreak of Ebola virus disease caused by Bundibugyo virus (BDBV) in the Democratic Republic of the Congo and Uganda has renewed attention to one of the least studied human-pathogenic...
01515
Reposted by The Lancet Infectious Diseases
The Lancet @thelancet.com · 28/07/2026
More people are ageing with HIV than ever before. A new Commission in The Lancet HIV calls for HIV care that supports healthy ageing through better prevention, person-centred care, & stronger health systems: tinyurl.com/32y4yez7 #IAS2026 #AIDS2026 @iasociety.bsky.social
Lancet infographic summarising the key findings of The Lancet HIV Commission on ageing and HIV.Lancet infographic summarising the key findings of The Lancet HIV Commission on ageing and HIV.Lancet infographic summarising the key findings of The Lancet HIV Commission on ageing and HIV.
0118
Reposted by The Lancet Infectious Diseases
The Lancet Microbe @lancetmicrobe.bsky.social · 29/07/2026
New research article #Tecovirimat treatment of clade II #mpox: a virological analysis of a randomised, double-blind, phase 3 trial www.thelancet.com/journals/lan... #IDSky #ClinMicro #ViroSky #OpenAccess #OA
114
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 30/07/2026
New Research Impact of directly observed treatment and extended age range of seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in Burkina Faso: a three-group, open-label, cluster-randomised, controlled trial www.thelancet.com/journals/lan...
thelancet.com
Impact of directly observed treatment and extended age range of seasonal malaria chemoprevention with sulfadoxine–pyrimethamine plus amodiaquine in Burkina Faso: a three-group, open-label, cluster-ran...
We observed no significant difference in parasite prevalence between programmatic SMC and SMC delivered through DOT in children younger than 5 years. Extending SMC to children aged 5–9 years reduced p...
000
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 29/07/2026
New Research Baloxavir marboxil, favipiravir, or oseltamivir in patients with non-severe symptomatic seasonal influenza (AD ASTRA): a phase 2, open-label, adaptive, randomised controlled trial www.thelancet.com/journals/lan...
thelancet.com
Baloxavir marboxil, favipiravir, or oseltamivir in patients with non-severe symptomatic seasonal influenza (AD ASTRA): a phase 2, open-label, adaptive, randomised controlled trial
Oral baloxavir, favipiravir, and oseltamivir accelerated influenza viral clearance rates in adults with early non-severe seasonal influenza at low risk of progression to severe disease. Baloxavir had ...
010
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 29/07/2026
New Research Effectiveness of scabies treatments in Italy (SCAB-net): a prospective observational study www.thelancet.com/journals/lan...
thelancet.com
Effectiveness of scabies treatments in Italy (SCAB-net): a prospective observational study
In this observational study from a high-income country, permethrin showed substantially reduced effectiveness compared with benzyl benzoate or ivermectin. These findings support reconsideration of cur...
111
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 28/07/2026
New Personal View Empiric tuberculosis treatment in hospitalised adults with advanced HIV disease in Africa: applying the therapeutic threshold to clinical practice www.thelancet.com/journals/lan...
thelancet.com
Empiric tuberculosis treatment in hospitalised adults with advanced HIV disease in Africa: applying the therapeutic threshold to clinical practice
Hospitalised adults with advanced HIV disease in sub-Saharan Africa experience high mortality, with tuberculosis, often disseminated and undiagnosed, being a leading cause. Despite this, initiation of...
023
Reposted by The Lancet Infectious Diseases
The Lancet Reg Health-Europe @lancetrh-europe.bsky.social · 23/07/2026
🆕evidence from 45,864 workers in England: unresolved #LongCOVID was linked to 38% lower odds of paid work and over 4× higher odds of changing working hours. shorturl.at/2yI71 @imperialcollegeldn.bsky.social @newcastleuni.bsky.social
shorturl.at
Long COVID symptom profiles, workforce participation, and working hours among adults in England: a population-based cohort study
Unresolved Long COVID was associated with worse employment outcomes. Symptom clusters highlighted the importance of considering heterogeneity in Long COVID when assessing workforce impacts and designi...
1157
The Lancet Infectious Diseases @thelancetinfdis.bsky.social · 27/07/2026
🎧 New Podcast On Hantavirus Infections Podbean: bit.ly/4vOGmJa Apple Podcasts: bit.ly/4bavbDh Spotify: tinyurl.com/ypfmujbk
bit.ly
Fernando Tortosa and Ariel Izcovich on hantavirus infections | The Lancet Infectious Diseases in conversation with
Fernando Tortosa and Ariel Izcovich discuss various aspects of hantavirus infections with a focus on the situation in Argentina, including transmission, epidemiology, clinical course, management, late...
012